Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Unicycive Therapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period [2]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Unicycive between March 29, 2024, and June 27, 2025, following a class action complaint filed on August 15, 2025 [2][4]. - Investors are encouraged to contact the law firm for discussions regarding their legal rights and options [1][4]. Group 2: Company Performance and Regulatory Issues - The complaint alleges that Unicycive misrepresented its readiness to meet FDA manufacturing compliance requirements for its New Drug Application (NDA) for oxylanthanum carbonate (OLC) [8]. - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in current good manufacturing practice (cGMP) compliance at a third-party vendor, leading to a significant stock price drop of over 40% [8]. - Following the issuance of a Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock fell nearly 30%, closing at $4.77 per share [8].

Illumina Inc. (NASDAQ:ILMN) stock is trading higher after the company reported better-than-expected third-quarter earnings.ILMN shares are climbing with conviction. Watch the momentum hereThe DNA sequencing company reported adjusted earnings of $1.34 per share, beating the consensus of $1.17.The company, in its prepared remarks, said the performance reflects the momentum in the clinical markets, where sequencing consumables revenue grew at a high single-digit rate year-over-year.The sales reached $1.084 bil ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare diseases https://t.co/Q9MejyU7T0 ...

Core Insights - Immunovant Inc. (NASDAQ:IMVT) has shown significant stock performance, increasing by 14.64% to close at $24.82 ahead of its upcoming Q3 earnings report [1][3] - The company is scheduled to announce its financial results on November 10, 2025, with a conference call planned to discuss the outcomes [2] - In the second quarter, Immunovant reported a widened net loss of $120.6 million, a 38% increase from $87.15 million year-over-year, while total operating expenses rose by 35% to $127 million from $94 million [2] Stock Performance - Immunovant's stock surged by 14.64% on Thursday, indicating strong investor interest prior to the earnings announcement [1][3] - The increase in stock price reflects market speculation and potential acquisition rumors involving Roivant Sciences Ltd., one of Immunovant's largest shareholders [3] Financial Highlights - The company experienced a significant increase in net loss and operating expenses in Q2, with net loss growing by 38% and operating expenses increasing by 35% compared to the previous year [2]

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Insmed Inc. (NASDAQ:INSM) is one of the best-performing stocks on Thursday. Insmed rallied for a fourth straight day to reach a new all-time high, as investors took heart from a highly optimistic business outlook for the full-year period, despite widening its net loss in the third quarter. At intra-day trading, the stock soared to its highest 52-week price of $194.70 before trimming a few cents to end the day just up by 16.33 perc ...

In the current session, Amgen Inc. (NASDAQ:AMGN) is trading at $291.80, after a 0.07% drop. Over the past month, the stock fell by 2.04%, and in the past year, by 7.92%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. Amgen P/E Compared to CompetitorsThe P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Guardant Health Inc. (NASDAQ:GH) is one of the best-performing stocks on Thursday. Guardant Health soared to a fresh record high on Thursday, as investors took heart from an impressive earnings performance and a higher growth outlook for the full-year period. During the trading session, Guardant Health Inc. (NASDAQ:GH) jumped to its highest level of $95.88 before paring gains to end the day just up by 27.87 percent at $92.41 apiec ...

Core Points - Evaxion A/S, a clinical-stage TechBio company, will provide a business update and report its Q3 2025 financial results on November 6, 2025 [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST, which is open to the public [2] - Evaxion specializes in developing AI-Immunology™ powered vaccines, focusing on immunotherapies for cancer, bacterial diseases, and viral infections [4] Company Overview - Evaxion A/S utilizes its proprietary AI platform, AI-Immunology™, to decode the human immune system and develop novel immunotherapies [4] - The company has a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting bacterial and viral diseases with high unmet medical needs [4] - Evaxion aims to transform patients' lives by providing innovative and targeted treatment options [4]

Accessibility StatementSkip Navigation Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE Trial Reinforces Its Position as a Leading LDL-C Lowering Therapy for Reducing Cardiovascular Events THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from t ...

HUTCHMED (China) (NasdaqGS:HCM) Update / Briefing October 31, 2025 08:00 AM ET Speaker0Hello, everyone. Good evening and good morning. Thank you for joining the HUTCHMED 2025 R&D Day event. For your reference, you can go to our website to download today's presentation slides. The performance and results of operations of the HUTCHMED group contained within this presentation are historical in nature, and the past performance is no guarantee of future results. As usual, we will have a Q&A session at the end wh ...